E-Mail
While neurological complications of COVID-19 in children are rare, in contrast to adults, an international expert review of positive neuroimaging findings in children with acute and post-infectious COVID-19 found that the most common abnormalities resembled immune-mediated patterns of disease involving the brain, spine, and nerves. Strokes, which are more commonly reported in adults with COVID-19, were much less frequently encountered in children. The study of 38 children, published in the journal
Lancet, was the largest to date of central nervous system imaging manifestations of COVID-19 in children. Thanks to a major international collaboration, we found that neuroimaging manifestations of COVID-19 infection in children could range from mild to severe and that pre-existing conditions were usually absent, says co-senior author Susan Palasis, MD, Division Head of Neuroradiology at Ann & Robert H. Lurie Children s Hospital of Chicago and Associate Professor of Radiology
COVID Vaccine: Here s What Experts Say You Can and Cannot Do After You Are Fully Vaccinated – NBC Chicago nbcchicago.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbcchicago.com Daily Mail and Mail on Sunday newspapers.
Chicago and IDPH confirm first case of COVID-19 P.1 variant in Illinois
Canton Daily Ledger
CHICAGO – The Chicago Department of Public Health (CDPH) and Illinois Department of Public Health (IDPH) announced the first case in Illinois of the COVID-19 variant called P.1. The P.1 variant was first identified in travelers from Brazil during routine airport screening in Tokyo, Japan, in early January but has subsequently been identified in several other countries.
A case of P.1 was first identified in the United States at the end of January in Minnesota and has since been identified in several other states. The case in Chicago was identified by the Pathogen Genomics research team at the Northwestern University Feinberg School of Medicine through sequencing analysis of a COVID-19 specimen. A follow-up investigation by CDPH found that a household contact of this individual had also recently been unwell with COVID-19, but neither this individual nor their household contacts reported tra
Researchers in England are deliberately exposing volunteers to the coronavirus that causes COVID-19. The goal is to speed up the development of new vaccines and treatments.
But exposing people to a potentially fatal disease with no particularly effective therapy strikes some as unnecessary, if not unethical.
Human challenge experiments differ from other studies of COVID-19 in a very important respect. The main difference is the control, says Christopher Chiu, an infectious disease researcher at Imperial College London and lead scientist for the challenge study.
He says with a challenge study, you know exactly when a person was exposed to the virus, and exactly how much virus they were exposed to.
Embed iframe src https://www.npr.org/player/embed/974903666/974941441 width 100% height 290 frameborder 0 scrolling no title NPR embedded audio player
MARY LOUISE KELLY, HOST: A controversial experiment has just begun in England. Researchers are deliberately exposing volunteers to the coronavirus that causes COVID-19. The goal is to speed up the development of new vaccines and treatments. But as NPR science correspondent Joe Palca reports, some question whether the benefits of these so-called human challenge experiments are worth the risks.
JOE PALCA, BYLINE: Human challenge experiments differ from other studies of COVID-19 in one crucial way.
CHRISTOPHER CHIU: The main difference is the control.